文献速递自身炎症与 IgG4 相关病

日本50例经NOD2基因分析确诊的Blau综合征临床特征与治疗

Clinical characteristics and treatment of 50 cases of Blau syndrome in Japan confirmed by genetic analysis of the NOD2 mutation.
PubMed 文献 · Ann Rheum Dis · 2020-07-09

该研究分析了日本50例携带NOD2突变的Blau综合征患者的临床资料,发现最常见突变为p.R334W,关节病变和眼部症状常见,7例失明;26例接受生物制剂(均为抗TNF)治疗,未接受生物制剂者出现失明,提示早期生物制剂治疗可能改善预后。

要点

  • 26例接受生物制剂(均为抗TNF),多联合MTX和/或泼尼松龙。
  • 失明患者均未接受生物制剂治疗,延迟诊治可致严重关节挛缩和失明。

核心结论

  • Blau综合征患者若诊断和治疗延迟,可能发生严重关节挛缩和失明;早期使用生物制剂可能改善预后。

研究设计与样本

  • 对50例经NOD2突变分析确认的Blau综合征患者进行临床资料收集,并在HEK293细胞中用报告基因法评估各NOD2突变体活性。

主要发现

  • 诊断后26例接受生物制剂治疗,均为抗肿瘤坏死因子制剂;仅3例单用生物制剂,其余联合甲氨蝶呤和/或泼尼松龙。
  • 失明患者均未接受生物制剂治疗。

临床怎么用

  • 对疑似Blau综合征患者应尽早进行NOD2基因分析以明确诊断。
  • 确诊后可考虑早期使用抗TNF生物制剂,常联合甲氨蝶呤和/或泼尼松龙,以改善预后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To collect clinical information and NOD2 mutation data on patients with Blau syndrome and to evaluate their prognosis. METHODS: Fifty patients with NOD2 mutations were analysed. The activity of each NOD2 mutant was evaluated in HEK293 cells by reporter assay. Clinical information was collected from medical records through the attending physicians. RESULTS: The study population comprised 26 males and 24 females aged 0-61 years. Thirty-two cases were sporadic, and 18 were familial from 9 unrelated families. Fifteen different mutations in NOD2 were identified, including 2 novel mutations (p.W490S and D512V); all showed spontaneous nuclear factor kappa B activation, and the most common mutation was p.R334W. Twenty-six patients had fever at relatively early timepoints in the disease course. Forty-three of 47 patients had a skin rash. The onset of disease in 9 patients was recognised after BCG vaccination. Forty-five of 49 patients had joint lesions. Thirty-eight of 50 patients had ocular symptoms, 7 of which resulted in blindness. After the diagnosis of Blau syndrome, 26 patients were treated with biologics; all were antitumour necrosis factor agents. Only 3 patients were treated with biologics alone; the others received a biologic in combination with methotrexate and/or prednisolone. None of the patients who became blind received biologic treatment. CONCLUSIONS: In patients with Blau syndrome, severe joint contractures and blindness may occur if diagnosis and appropriate treatment are delayed. Early treatment with a biologic agent may improve the prognosis.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Matsuda T, Kambe N, Ueki Y, et al. Clinical characteristics and treatment of 50 cases of Blau syndrome in Japan confirmed by genetic analysis of the NOD2 mutation. Ann Rheum Dis. 2020. PMID: 32647028. doi:10.1136/annrheumdis-2020-217320

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。